Find the products and resources you are looking for!
Get in touch!
Our local employees are always happy to answer your questions. Highly trained and experienced teams in your country can provide quick, helpful, and comprehensive support.
Miltenyi Biotec Inc.
2303 Lindbergh Street
Auburn, CA 95602
USA
Phone: +1 800 FOR MACS
+1 530 888 8871
Fax: +1 530 888 8925
E-Mail: macs@miltenyibiotec.com
Web: www.miltenyibiotec.com
For immediate technical support, use our live chat.
Connect with usOrders:
Phone: +1 866 811 4466
Fax: +1 877 591 1060
E-Mail: orderdesk@miltenyibiotec.com
Technical support - Research products:
Phone: +1 800 FOR MACS
Fax: +1 530 745 2806
E-Mail: science@miltenyibiotec.com
Technical support - Clinical products:
Phone: +1 800 FOR MACS
Fax: +1 530 745 2806
E-Mail: science@miltenyibiotec.com
Miltenyi Biotec distribution:
As a global market leader with numerous subsidiaries and distributors, Miltenyi Biotec is committed to providing our customers around the world with the highest quality products. In addition to direct selling in more than 20 countries in North America, Europe and Asia/Pacific, Miltenyi Biotec also provides support for our customers through an extensive distributor network covering dozens of additional countries.
Our local employees are always happy to answer your questions. Highly trained and experienced teams in your country can provide quick, helpful, and comprehensive support.
Miltenyi Biotec Inc.
2303 Lindbergh Street
Auburn, CA 95602
USA
Phone: +1 800 FOR MACS
+1 530 888 8871
Fax: +1 530 888 8925
E-Mail: macs@miltenyibiotec.com
Web: www.miltenyibiotec.com
For immediate technical support, use our live chat. Connect with us
Orders
Phone: +1 866 811 4466
Fax: +1 877 591 1060
E-Mail: orderdesk@miltenyibiotec.com
Technical support - Research products
Phone: +1 800 FOR MACS
Fax: +1 530 745 2806
E-Mail: science@miltenyibiotec.com
Technical support - Clinical products
Phone: +1 800 FOR MACS
Fax: +1 530 745 2806
E-Mail: science@miltenyibiotec.com
As a global market leader with numerous subsidiaries and distributors, Miltenyi Biotec is committed to providing our customers around the world with the highest quality products. In addition to direct selling in more than 20 countries in North America, Europe and Asia/Pacific, Miltenyi Biotec also provides support for our customers through an extensive distributor network covering dozens of additional countries.
In this application protocol, we describe the differentiation of human pluripotent stem cells (hPSCs) into cardiomyocytes, the isolation of the resulting cardiomyocytes, and their analysis using flow cytometry or immunofluorescence microscopy.
Column | Max. number of labeled cells | Max. number of total cells | Separator |
---|---|---|---|
Depletion or positive selection | |||
LS | 5×10⁶ | 5×10⁶ | MidiMACS™, QuadroMACS™, VarioMACS, SuperMACS II |
autoMACS | 1×107 | 1×107 | autoMACS Pro |
View timeline
With this protocol, cardiomyocytes can be generated from hPSCs with efficacies of up to 80%, giving rise to contracting cells in 9–12 days.
▲ Note: Testing of various cell numbers and CHIR99021 concentrations is recommended to optimize differentiation for each individual hPSC line. The diagram below provides a graphical overview of the procedure.
▲Note: The effectiveness of differentiation depends on the number of seeded cells. Therefore, it is crucial to determine the cell number that leads to optimal differentiation. Different cell numbers might be required for different hPSC lines.
Replace medium in each well with 1 mL StemMACS iPS-Brew XF.
Replace medium in each well with 2 mL of RPMI 1640 + L-glutamine + B-27 Supplement, minus insulin.
Replace medium in each well with 2 mL of RPMI 1640 + L-glutamine + B-27 Supplement, minus insulin.
Replace medium in each well with 2 mL of RPMI 1640 + L-glutamine + B-27 Supplement w/insulin, and continue to do so every 2–3 days.
The development of highly efficient cardiac-directed differentiation methods makes it possible to generate large numbers of cardiomyocytes.1,4 However, due to varying differentiation efficiencies, cardiomyocyte populations must be further enriched for downstream applications.
To achieve highest possible purity and recovery during cell separation, first dissociate the monolayer cultures into a single-cell suspension using the Multi Tissue Dissociation Kit 3.
▲ Note: Perform all steps under sterile conditions.
▲ Note: The dissociation protocol is optimized for use with 12-well or 6-well plates.
Separate the cardiomyocytes using the PSC-Derived Cardiomyocyte Isolation Kit, human. Follow the protocol of the kit data sheet.
The isolation is performed either as a single-step or two-step protocol, depending on the initial differentiation efficiency (see isolation strategy below). As a general guideline, we recommend performing the second (positive selection) step if the culture contains <50 % of cardiomyocytes.
The standard protocol enables enrichment of cardiomyocytes from up to 5×10⁶ total cells, and upscaling is possible for up to 1×10⁷ total cells.
Download kit data sheet
In recent years, various protocols to differentiate PSCs into cardiomyocytes have been published. However, the resulting populations are not homogeneous, but rather composed of a variety of cardiomyocyte subtypes or subpopulations, as well as non-cardiomyocyte cell types.
Different cardiomyocyte subpopulations can be identified and analyzed using techniques such as patch clamp, immunocytochemistry or flow cytometry. Compared to other techniques, flow cytometry is a fast and efficient method to analyze and quantify different cell types within a cell population, without difficult techniques or genetic engineering of the starting material.
Besides analysis by flow cytometry, cardiomyocytes are often examined by microscopy using immunofluorescence staining. Recombinantly engineered REAfinity™ Antibodies enable unambiguous analysis of cardiomyocytes.
The following is a list of relevant resources that might be of interest:
Unless otherwise specifically indicated, Miltenyi Biotec products and services are for research use only and not for therapeutic or diagnostic use.
autoMACS, CliniMACS, the CliniMACS logo, CliniMACS Prodigy, CryoMACS, CytoMix, CytoStim, DendriMACS, ExiTron, ExpAct, FeraSpin, FeraTrack, GadoSpin, gentleMACS, LIFE 18, LIFE 21, MACS, the MACS logo, MACSductin, MACSelect, MACSfectin, MACSflex, MACSiBead, MACSiMAG, MACSmix, MACSprep, MACSQuant, MACSQuantify, MACSxpress, MidiMACS, MiniMACS, miRXplore, MultiMACS, NeuroBrew, NiraWave, OctoMACS, PepTivator, pMACS, PolySon, PrepProtect, QuadroMACS, REAfinity, REAlease, Rheo, StemMACS, StraightFrom, SuperAmp, SuperMACS, TexMACS, TheraSorb, thermoMACS, TransAct, Tyto, the Tyto logo, VarioMACS, Vio, Viobility, VioBlue, VioBright, VioGreen, Viscover, and µMACS are registered trademarks or trademarks of Miltenyi Biotec GmbH and/or its affiliates in various countries worldwide. Ficoll-Paque is a trademark of GE Healthcare companies. Vectofusin-1 is a registered trademark of Genethon. All other trademarks mentioned in this document are the property of their respective owners and are used for identification purposes only. Copyright © 2018 Miltenyi Biotec GmbH and/or its affiliates. All rights reserved.